Domestic third-party medical inspection institutions are committed to meeting people's growing health management needs, and improving the experience of patients' health testing and the accuracy and efficiency of testing by introducing advanced medical equipment and technical means and expanding the scope of services. Jinyu Testing is in a leading position in the industry, and with its outstanding testing capabilities and continuous improvement of innovation capabilities, it has continuously launched more high-quality testing items to meet the diverse testing needs of clinicians and patients.
Under the guidance of the clinical and disease-oriented full-product strategy, Jinyu Testing has formed a complete and comprehensive testing and diagnosis technology system relying on a complete laboratory testing technology platform. At the same time, by comprehensively promoting medical examination 40 strategy, Jinyu Testing has 82 types of medical laboratory technology platforms in 8 university disciplines. At present, Jinyu Testing can provide more than 3,900 test items, and the test results can be recognized by more than 70 countries and regions around the world.
In the digital era, Jinyu Testing actively participates in the tide of the times and meets the challenges brought by structural transformation and upgrading. As early as 2020, Jinyu Testing took the lead in proposing a digital transformation strategy and formulated a construction plan of "two libraries, one center and one base", in order to promote the intelligence of the whole process of medical testing. At this stage, Jinyu Testing's insistence on digital transformation is gradually emerging, and has brought about the growth of a number of businesses. The construction of a one-stop service platform for the whole journey of customers focused on by Jinyu Testing last year has broken through the online service of nearly 400,000 doctors across the country, which can greatly meet the needs of patients for online medical treatment and reduce the burden of diagnosis and treatment in offline hospitals. The self-developed TNGS sample preparation system was successfully launched, which greatly improved the efficiency of reporting and diagnosis, and continuously empowered clinical practice to achieve accurate diagnosis and treatment.
In addition to the achievements in digital transformation, Jinyu Testing has also continued to make efforts in R&D and innovation capabilities, and driven its own development with innovation. By continuing to increase R&D investment in key disease areas such as infectious diseases, blood diseases, and endocrine diseases, a number of businesses have maintained a growth trend in many quarters, and in the first three quarters of 2023 alone, the number of newly developed projects has reached more than 300, which can meet the needs of clinical disciplines, continue to maintain industry leadership, and lead the forefront of industry development.
Jinyu Testing is also committed to holding public welfare activities to give back to the society with its own strength. For example, a number of public welfare activities for early tumor screening held by Jinyu Testing, combined with the large-scale testing cost reduction strategy, the tumor gene methylation service launched by Jinyu Testing has been recognized by the clinical community. In just a few years, the annual testing volume of the tumor gene methylation program has reached 150,000 cases. It is believed that in the future, Jinyu Testing will continue to give full play to its own advantages, promote continuous technological progress, and help build a healthy China.
Disclaimer: The market is risky, choose carefully! This article is for reference only and is not intended as a basis for trading.